These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28229536)

  • 1. The physical properties of generic latanoprost ophthalmic solutions are not identical.
    Kolko M; Koch Jensen P
    Acta Ophthalmol; 2017 Jun; 95(4):370-373. PubMed ID: 28229536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of physical properties and dose equivalency of generic versus branded latanoprost formulations.
    Angmo D; Wadhwani M; Velpandian T; Kotnal A; Sihota R; Dada T
    Int Ophthalmol; 2017 Apr; 37(2):423-428. PubMed ID: 27334605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variation in Number of Doses, Bottle Volume, and Calculated Yearly Cost of Generic and Branded Latanoprost for Glaucoma.
    Queen JH; Feldman RM; Lee DA
    Am J Ophthalmol; 2016 Mar; 163():70-74.e1. PubMed ID: 26596398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generic versus brand-name North American topical glaucoma drops.
    Mammo ZN; Flanagan JG; James DF; Trope GE
    Can J Ophthalmol; 2012 Feb; 47(1):55-61. PubMed ID: 22333853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective study comparing Xalatan
    Diagourtas A; Kagelaris K; Oikonomakis K; Droulias A; Kokolakis N; Papaconstantinou D
    Eur J Ophthalmol; 2018 Jul; 28(4):378-384. PubMed ID: 29952663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stability of latanoprost in generic formulations using controlled degradation and patient usage simulation studies.
    Velpandian T; Kotnala A; Halder N; Ravi AK; Archunan V; Sihota R
    Curr Eye Res; 2015 May; 40(6):561-71. PubMed ID: 25494824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the Xal-Ease latanoprost delivery system.
    Semes L; Shaikh AS
    Optometry; 2007 Jan; 78(1):30-3. PubMed ID: 17208672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the introduction of generic latanoprost on glaucoma medication adherence.
    Stein JD; Shekhawat N; Talwar N; Balkrishnan R
    Ophthalmology; 2015 Apr; 122(4):738-47. PubMed ID: 25680226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of intraocular pressure in glaucoma subjects treated with Xalatan versus generic latanoprost.
    Egan P; Harris A; Siesky B; Abrams-Tobe L; Gerber AL; Park J; Holland S; Kim NJ; Januleviciene I
    Acta Ophthalmol; 2014 Aug; 92(5):e415-6. PubMed ID: 24373426
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of latanoprost when stored at room temperature.
    Mochizuki H; Itakura H; Takamatsu M; Kiuchi Y
    Hiroshima J Med Sci; 2008 Jun; 57(2):69-72. PubMed ID: 18717189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma.
    Rouland JF; Traverso CE; Stalmans I; Fekih LE; Delval L; Renault D; Baudouin C;
    Br J Ophthalmol; 2013 Feb; 97(2):196-200. PubMed ID: 23203707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure.
    Liu JH; Kripke DF; Weinreb RN
    Am J Ophthalmol; 2004 Sep; 138(3):389-95. PubMed ID: 15364220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%.
    García-Feijoo J; Martínez-de-la-Casa JM; Castillo A; Méndez C; Fernández-Vidal A; García-Sánchez J
    Curr Med Res Opin; 2006 Sep; 22(9):1689-97. PubMed ID: 16968572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of a preservative-free latanoprost cationic emulsion (Catioprost) and a BAK-preserved latanoprost solution in animal models.
    Daull P; Buggage R; Lambert G; Faure MO; Serle J; Wang RF; Garrigue JS
    J Ocul Pharmacol Ther; 2012 Oct; 28(5):515-23. PubMed ID: 22671995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ocular hypotensive effects and safety over 3 months of switching from an unfixed combination to latanoprost 0.005%/timolol maleate 0.5% fixed combination.
    Inoue K; Okayama R; Higa R; Sawada H; Wakakura M; Tomita G
    J Ocul Pharmacol Ther; 2011 Dec; 27(6):581-7. PubMed ID: 22011049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of latanoprost and timolol in pediatric glaucoma: a phase 3, 12-week, randomized, double-masked multicenter study.
    Maeda-Chubachi T; Chi-Burris K; Simons BD; Freedman SF; Khaw PT; Wirostko B; Yan E;
    Ophthalmology; 2011 Oct; 118(10):2014-21. PubMed ID: 21680022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
    Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
    Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications.
    Noecker RJ; Walt JG
    Am J Ophthalmol; 2006 Jan; 141(1 Suppl):S15-21. PubMed ID: 16389056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of 15-keto latanoprost on intraocular pressure and aqueous humor dynamics in monkey eyes.
    Wang RF; Gagliuso DJ; Mittag TW; Podos SM
    Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4143-7. PubMed ID: 17724199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are generic topical prostanoids the way forward in the care of glaucoma patients? - Yes.
    Titcomb LC
    Eye (Lond); 2013 Sep; 27(9):999-1001. PubMed ID: 23807388
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.